Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 27Non-metastatic Castration-resistant Prostate Cancer 2Neoplasm Metastasis 2Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Prostate Cancer Metastatic 1Non-metastatic Prostate Cancer 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms by Site 1Neoplasms 1Metastatic Castration-Resistant Prostate Cancer 1Low Risk Prostate Cancer 1Genital Neoplasms, Male 1Genital Diseases, Male 1Castration Levels of Testosterone 1Advanced Prostate Carcinoma 1

Interventions

Abiraterone Acetate 3enzalutamide 2abiraterone 2Prednisone 2sapanisertib 1relugolix 1onvansertib 1apalutamide 1abemaciclib 1Prednisolone 1Methylprednisolone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Castration-Resistant Prostate Cancer × apalutamide × Clear all
NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
48 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡